Personalized nutrition to support recovery after a Whipple (pancreatic) operation
Official title: Implication of Nutritional Intervention in Enhanced Recovery After Surgery for Whipple Procedure/Pylorus Preserving Pancreatoduodenectomy
Run by University of Veterinary and Animal Sciences, Lahore - Pakistan · NCT07560540 · Data updated 2026-11-12
This will test whether personalized nutrition plans (calorie and protein targets with enteral or IV feeds) help people having a Whipple operation recover faster and have fewer complications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Veterinary and Animal Sciences, Lahore - Pakistan Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Lahore) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07560540 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) scheduled for an elective Whipple/PPPD for malignancy of the pancreatic head, distal common bile duct, periampullary region, or duodenum are ideal candidates.
✕Probably not a fit
Patients having emergency procedures, those undergoing Whipple for non-malignant reasons, or those with severe preoperative issues preventing oral intake are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study will enroll 20 adults undergoing elective Whipple procedure (open or laparoscopic) at Shalamar Hospital in Lahore and deliver personalized medical nutrition therapy before and after surgery. Nutrition targets are 25–30 kcal/kg and 1.2–1.5 g/kg protein with enteral or parenteral support as needed, and care will follow ERAS guidelines. Investigators will track body composition, weight maintenance, biochemical labs (LFTs, RFTs, CBC, CRP, electrolytes, coagulation, HbA1c), muscle preservation, postoperative complications, and length of stay. Follow-up visits are planned at two weeks, three months, and six months, with nutrition adjusted for patients who do or do not receive chemotherapy.
Why it matters
Potential benefit: If successful, this could reduce postoperative complications, preserve muscle and nutritional status, and shorten hospital stays after a Whipple operation.
How similar studies have gone: Previous work on perioperative nutrition and ERAS in abdominal and pancreatic surgery suggests benefits for recovery and complications, but tailored nutrition programs specifically after Whipple are less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Malignancy of; * Distal common bile duct * Pancreatic head * Periampullary * Duodenal * Patients scheduled for elective Whipple's procedure (laparoscopic and open) * Age 18 and above Exclusion Criteria: * Patients undergoing Whipple's procedure for reasons other than malignancy * Patients undergoing emergency procedures * Patients with significant preoperative complications prohibiting oral intake * Age below 18
Where it's running
-
Shalamar Hospital
Lahore, Pakistan Recruiting
Study contacts
- Study coordinator: Javeriya Afzal, MPhil Food and Nutrition
- Email: javeriyaafzal23@gmail.com
- Phone: 00923244090078
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.